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Cancer genomicsn genome sequence and progress in sequencing and bioinformatic technologies
have enabled genome-wide investigation of somatic mutations in human cancers. This article brieﬂy reviews
challenges arising in the statistical analysis of mutational data of this kind. A ﬁrst challenge is that of
designing studies that efﬁciently allocate sequencing resources. We show that this can be addressed by two-
stage designs and demonstrate via simulations that even relatively small studies can produce lists of
candidate cancer genes that are highly informative for future research efforts. A second challenge is to
distinguish mutated genes that are selected for by cancer (drivers) from mutated genes that have no role in
the development of cancer and simply happened to mutate (passengers). We suggest that this question is
best approached as a classiﬁcation problem and discuss some of the difﬁculties of more traditional testing-
based approaches. A third challenge is to identify biologic processes affected by the driver genes. This can be
pursued by gene set analyses. These can reliably identify functional groups and pathways that are enriched
for mutated genes even when the individual genes involved in those pathways or sets are not mutated at
sufﬁcient frequencies to provide conclusive evidence as drivers.
© 2008 Elsevier Inc. All rights reserved.Introduction
Genome-wide somatic mutation studies
The discovery of genes mutated in human cancers has provided
key insights into the mechanisms underlying tumorigenesis and has
proven useful for the design of targeted therapeutic approaches [1].
Recently, the availability of the human genome sequence and progress
in sequencing and bioinformatic technologies have enabled genome-
wide investigation of somaticmutations in human cancers [2,3]. These
studies exemplify an emerging trend that includes other large-scale
sequencing efforts of cancer genomes [4]. Analysis focuses on the
comparison between the sequences found in tumor samples and those
of the originating normal tissues. The goal of this comparison is to
identify regions of the genome that differ frequently enough to
warrant further investigation of potential causal mechanisms. So far
this comparison has focused primarily on coding sequences of well-
annotated genes.
Passengers and drivers
Cancer arises as the result of successive clonal expansions driven
by cells that acquire a selective advantage through mutations.
Generally, alterations are the result of errors that arise during the
process of DNA replication during cellular expansion. These errors arel rights reserved.associated with mistakes during DNA polymerization or with external
agents, such as carcinogens, and may or may not provide a selective
advantage to the affected cell. As a result, before it undergoes a new
mutation that provides a selective advantage, a cell will typically
accumulate other alterations that are neutral with respect to selection.
Mutations that are disadvantageous may also occur, but these will
selected against during tumorigenesis and will not be present in
clonal expansions of tumor cells. Genome-wide somatic mutation
studies will therefore identify two types of mutations: the “drivers”—
those providing a selective advantage—and the “passengers”—those
neutral to the selection process [5]. Genes capable of harboring driver
mutations are referred to as “driver genes.” Similarly, genes that are
not driver genes are referred to as “passenger genes.” One of themajor
goals of the analysis of data from genome-wide somatic mutation
studies is the ranking of genes based on the likelihood that they may
be drivers.
Mountains and hills
If one represents likely driver genes as relief features on a map, the
resulting landscapes will contain a small number of major mountains,
representing genes that are mutated in the majority of cancers, and a
much larger number of hills, representing the genes that are mutated
at relatively low frequency. This general genomic landscape is a
common feature of both breast and colorectal tumors [3]. So far,
cancer research has focused on the gene mountains. The ability to
analyze the sequence of virtually all protein-encoding genes in
cancers has shown that the vast majority of mutations in cancers,
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such mountains, emphasizing the heterogeneity and complexity of
human neoplasia. This new view of cancer is consistent with the idea
that a large number of mutations, each associated with a small ﬁtness
advantage, drive tumor progression [6,7]. But while the number of
potential driver genes is large, changes appear to occur in a more
limited number of “driver” pathways [1,4,8–11].
This landscape has important implications for the statistical design
and analysis of genome-wide studies of somatic mutations in cancer.
Design
Choice of tumor samples
The successive bottlenecks that characterize the evolution of a
tumor are driven by mutations that tend to occur at different stages—
mutations of certain pathways are typically important earlier on,
while others are more likely to occur at a later stage. For example, in
colorectal cancer, mutations that are associated with adenoma
formation are typically different from those that contribute to the
progression of those adenomas to carcinomas. Therefore, initial
studies whose primary goal is to efﬁciently identify the largest
number of drivers with the fewest samples have concentrated on
advanced disease samples. This is because neoplasia is a dynamic
process and advanced lesions harbor all the driver mutations present
in earlier in that lesion, though the converse is not true. The
identiﬁcation of mutations in advanced lesions also provides the
opportunity to determine the timing of these alterations during
tumorigenesis, by examining earlier lesions from the same patients
[12].
Prior to undertaking extensive sequence analysis, our group tested
whether 300 known mutations and polymorphisms in a panel of 100
colorectal cancers could be detected using the ﬁnal algorithms
described in [3]. The sensitivity for detecting these mutations was
100%. Challenges arise from contamination of samples with surround-
ing nonneoplastic tissue and heterogeneity within tumors. Non-
tumor-cell contamination can substantially reduce the sensitivity of
sequencing analysis. It was for exactly this reason that all the cases we
analyzed were cell lines or xenografts: the only human DNA in these
samples is derived from the cancers. In our approach, we only describe
clonal mutations, that is, those present in the vast majority (if not all)
of the neoplastic cells within the specimen. As discussed in detail in
[12], such mutations are the most important for driving the
tumorigenic process.
Another important consideration has been the exclusion of
samples with such widespread genetic alterations that the informa-
tion provided is minimal. For example, in their genome-wide
mutation analysis of colorectal cancer Sjöblom et al. [2] excluded
samples with mismatch repair mutations. An important goal of future
studies should be that of characterizing from an epidemiological
standpoint the frequency of tumors wherein a given gene or pathway
plays the role of a driver. This will require different designs, larger
sample sizes, and consideration of the patient population to which the
estimated frequencies should be applied.
Multistage sampling
Despite recent progress in sequencing technologies, genome-wide
analysis of somatic mutations in cancer remains a major undertaking.
Time and cost considerations should be a factor in determining the
scope of a study and the sample sizes. Signiﬁcant gains in efﬁciency
can be achieved by multistage approaches, in which an initial
“discovery” phase is performed ﬁrst on a genome-wide scale, followed
by a “validation” phase inwhich genes that emerge as candidates from
the discovery phase are evaluated in additional samples. For example
Sjöblom et al. [2] performed a genome-wide analysis of all the genesin the CCDS database on 11 samples, followed by analysis of all the
genes that were mutated at least once in 24 additional samples. Wood
et al. [3] adopted a similar design, integrated by a third phase with the
goal of providing a more accurate estimate of mutation frequencies on
a yet smaller set of genes. In the Wood study about 4% of the genes in
colon cancer and about 5% in breast cancer were found to be mutated
in the discovery stage and thus sequenced in the validation stage.
Simulation of mutation analysis data
To facilitate design and analysis of mutation studies, we developed
software to perform in silico experiments that exactly replicate the
experimental procedure. They represent mutations found in a
hypothetical genome with a known composition of driver and
passenger genes. It is reasonable to assume that the likelihood of a
random mutation will apply to individual nucleotides and that the
precise base that is mutated as well as its neighbors is important in
evaluating the probability of a mutational event. We will refer to this
as the mutation's “context.” Therefore, each gene's probability of
accumulating a random mutation will depend on its size and
nucleotide composition. Also, in real experiments, if quality control
criteria are applied to sequencing results, the number of nucleotides
successfully sequenced is generally less than 100%. The actual fraction,
or “coverage,” should be a consideration.
In the simulation presented here we considered each gene in turn
and simulated, for each nucleotide context, the number of mutations
from a binomial distribution with success probability equal to either
(a) the context-speciﬁc passenger rate or (b) a randomly selected rate,
higher than the passenger rate. These rates were drawn from a
distribution of mountains and hills that mimicked what was observed
in real experiments. To generate mutations in driver genes, we used
the empirically observed rates of the 160 genes found to bemutated in
colorectal cancers in both the discovery and the validation screen of
Wood et al. [3]. The number of available nucleotides in each context
was based on the RefSeq database. For the binomial calculation, the
gene sizes were adjusted using the proportion of nucleotides
successfully sequenced in Wood et al. [3] for that particular gene
and by the number of samples available in the discovery screen. We
then considered all genes for which at least one mutation was
generated, and repeated the process with samples to simulate the
validation screen. The software used for the simulations presented
here is available as part of a package called CancerMutationAnalysis
[3]. Users can specify passenger and driver rates, sample sizes, gene
sizes and composition, gene-speciﬁc counts of successfully sequenced
nucleotides, and other variables.
Sensitivity and positive predictive values in one and two-stage designs
Using this tool, we assessed the trade-offs associated with
choosing the sample sizes in one- and two-stage studies. To concisely
capture the effectiveness of a speciﬁc choice, we focus on the
properties of lists composed of the top T most promising genes,
where “most promising” is deﬁned in terms of the likelihood ratio test
[13] for the null hypothesis that the gene is mutated at the same rate
as the passenger mutation rate. We report the sensitivity—the
proportion of genes included in the top T among all drivers, and the
positive predictive value (PPV)—the proportion of drivers among the
top T genes. The sensitivity is related to statistical power, but it is not
the same for two reasons: it is a probability across a set of genes,
rather than a probability for a single gene over multiple experiments,
and the driver mutations rates are allowed to vary.
Fig. 1 illustrates results for lists composed of the top 300 genes.
Data are simulated assuming that there are 1000 drivers in the
genome. Both the sensitivity and the PPV reach their maximumvalues
of 0.3 and 1.0 at relatively small sample sizes. Even a relatively small
experiment with 10 discovery and 20 validation samples has a PPV in
Fig. 1. Sensitivity (left) and positive predictive value (right) of alternative sample sizes. The black continuous line represents a single-stage design, while the dotted lines represent
two-stage designs with different validation sample sizes (20, 40, or 60). Because we considered lists of the top 300 genes, and simulated data assuming that there are 1000 drivers in
the genome, the sensitivity can be at most 0.3.
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of a study with 10 discovery and 20 validation samples is 98%.
The passenger rates used in Fig. 1 correspond to the intermediate
scenario of Wood et al. [3]. At higher rates the PPV and sensitivity are
lower, though even small studies remain informative. For example, the
PPV of a study with 10 discovery and 20 validation samples remains
around 70%. An important assumption in this analysis is that the
passenger rates are the same across genes and samples. If these rates
were actually to vary across genes, larger samples would be required
to achieve similar performance.
Studies of optimal two-stage genotyping in population-based
association studies using SNPs have suggested that two-stage designs
halve the cost for a given power in that context [14]. The analyses
presented here suggest that in mutation analysis studies the gains are
likely to be comparable. For example, from Fig. 1, the sensitivity of a
studywith 20 discovery samples and no validation (that is, a one-stage
study) is comparable to that of a study with 10 discovery and 20
validation samples, while the sequencing effort involved is approxi-
mately 55% of the original effort, assuming that about 5% of the genes
included in the discovery screen will be sequenced in the validation
screen.
Finally, the distribution of driver rates used in the simulations
presented in Fig. 1 covers a broad range. We also examined the ability
of a study to identify the larger hills or “major drivers.” We assume
there are 150 major drivers and their rates are drawn from the
distribution of the top 20 candidate colorectal cancer genes in Wood
et al. [3]. The sensitivity of the list of top 150 genes in a study with 10
discovery and 20 validation samples is 59% and the PPV is 58%. A
sensitivity of 80% is achieved by studies with 30 discovery and 60
validation samples, and a sensitivity of 83% with 40 discovery and 60
validation samples.
Analysis
Goals
The overarching goal of data analysis in somatic mutation studies
of cancer is to prioritize the research that follows. Two tasks are
especially important: to provide quantitative measures useful for
ranking the genes that are most worthy of further investigation, and
to point to pathways or other gene classes whose analysis may
reveal important mechanistic evidence or suggest therapeutic
approaches. In this section we review statistical challenges related
to these two tasks.Passenger mutation rates
An important role in statistical analyses is played by the rate at
which passenger mutations appear in cancer samples. This is a
difﬁcult quantity to estimate empirically, because the rate refers to
hypothetical cell populations that underwent the same mutagenic
exposures and clonal bottlenecks as a real cancer, but where those
bottlenecks occurred for reasons other than selection. Wood et al. [3]
approximated this situation by studying portions of the genomes of
cancers that are a priori highly unlikely to harbor regions whose
mutation would provide an advantage. In this way they obtained a
lower bound for the passenger rates. Independently, estimates of the
passenger mutation rates were also obtained through the quantiﬁca-
tion of synonymous missense mutations. As synonymous changes are
expected not to be selected for or against as strongly during
tumorigenesis, such changes can be used as a tool to approximate
passenger mutation rates. The analysis of synonymous mutations
provided two estimates of the nonsynonymous (NS) mutation rate.
One estimate was based on the ratio of nonsynonymous to synon-
ymous mutations in the human germline determined from the
HapMap project, and was considered to be a minimum because the
ratio of nonsynonymous to synonymous coding regionmutationsmay
be higher in the germline than in tumors because of greater negative
selection for NSmutations in the germline. An additional estimatewas
derived by calculating the expected ratio of non-synonymous to
synonymous changes after accounting for codon usage of RefSeq
genes and the different mutation spectra observed in colorectal and
breast cancers. This estimate was considered a maximum because it
does not take into account the fact that nonsynonymous mutations
that retard cell growth will be selected against during tumorigenesis.
The fraction of such nonsynonymous alterations that retard cell
growth may be quite large, as studies in yeast suggest that alterations
of up to 40% of protein coding genes can lead to quantitative growth
defects [15].
Passenger rates vary considerably from tumor to tumor, undoubt-
edly determined by their intrinsic mutability and the number of
generations and bottlenecks through which they have evolved.
Sorting drivers from passengers
To prioritize future studies it is useful to assign, to each of the
genes in which mutations are found a score that captures whether it
is more plausibly a driver or a passenger. Statistically, this question
can be formulated, as a ﬁrst approximation, as that of classifying
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passenger rate. A useful framework for this analysis is that of
classiﬁcation: in our case, classiﬁcation of genes into passengers and
drivers. Probabilistic classiﬁcation is especially useful, as it provides
for each gene a probability of being a driver. Wood et al. [3], for
example, use an empirical Bayesian approach adapted from Efron et
al. [16] to derive these probabilities. The key feature underlying this
approach is the in silico generation of a study identical to the one
performed, except that all mutations occur at the passenger rates;
i.e., there are no driver genes. For each gene a score is then
computed for both the observed and in silico data. The distribution
of these scores in the real experiment is then analyzed as a mixture
of passengers' scores, drawn from the distribution generated in
silico, and drivers' scores, drawn from a different and unknown
distribution. For each gene, the probability of belonging to each of
these two mixture components provides the classiﬁcation
probability.
Alternative approaches proceed by testing for each gene the null
hypothesis that the mutation rate is the same as the passengers rate.
One challenge in this context is to devise an appropriate multiple
testing adjustment. Traditional frequentist approaches have serious
limitations. First, when data are collected in a two-stage approach,
only genes that harbored, say, at least one mutation in the discovery
screen is analyzed in the validation screen. As a result of this, P values
are very computationally-intensive to evaluate. Second, P values will
be 1 for all genes in which no mutations are found. This makes it
impossible to provide adjustments that account for the size and
coverage of those genes, which constitute the vast majority. This can
lead to an excessive multiple testing correction of the P value
calculations and an underestimate of the number of genes mutated
at higher than passenger rates.
Gene sets
A third challenge is to identify biologic processes affected by the
driver genes. To address this question, their putative roles based on
sequence similarity, membership in known functional groups and
pathways, and potential interactions with other proteins can be
examined. These analyses can reliably identify functional groups and
pathways that are enriched for mutated genes, even when the
individual genes involved in those pathways are not mutated
sufﬁciently often to provide conclusive evidence. Statistically, the
goal is the evaluation of a set of genes as a single candidate driver. A
simple approach along these lines is to consider an entire functional
gene set as a pool of nucleotides at risk of somaticmutations and apply
the same techniques used for individual genes directly to the whole
pool [11]. This is a sensitive approach and is easy to implement.
Possible drawbacks include an excessive emphasis on sets that include
a single gene mutated at very high frequency and a lack of
consideration of the sizes of the genes in which mutations were and
were not found. Alternatively, genes can be sorted by a score that
reﬂects the likelihood of being mutated at rates higher than the
passenger rates, and a test can be used to compare the scores inside
and outside functional gene sets, similarly to what was previously
used for microarray expression analysis [17–19]. Gene set analysis can
also be complemented by approaches that use natural language
processing techniques to search the PubMed database for relation-
ships between genes, highlighting additional candidate associations
[20].
Conclusion
We have brieﬂy reviewed the main analysis challenges arising in
genome-wide studies of somatic mutations in cancer. We showed via
simulations that even with relatively small sample sizes, two-stage
designs can be highly informative for future studies, and brieﬂyreviewed the lessons we learned about such analyses from the efforts
of Sjöblom et al. [2] and Wood et al. [3].
In statistical analyses of mutation frequency alone, the drivers are
equated to the genes that are mutated at higher frequencies than the
passengers. This is not the same as being a true cancer gene. The
former can be precisely deﬁned and investigated using cancer genome
sequencing studies. The latter, while interpretable in many ways,
implies some additional independent validation of causality. We
believe that sequencing data can, at best, only point to candidates
worthy of further study.
The points presented here are applicable to studies employing the
new generations of high-throughput massively parallel sequencing
technologies, as they are similar to the classic Sanger sequencing
methods that formed the bases for the current analysis. However,
along with the promise that these new technologies offer, they also
present unique challenges. For example, the above-cited studies were
only possible because of the efﬁcient and proven strategies for
eliminating technical false positives that have been developed over
the 30-year history of Sanger sequencing. Similar strategies will have
to be developed for these new approaches. Additionally, all of the
leading new technologies rely on digital sequencing (i.e., single
molecule sequencing), which will both simplify and complicate
mutational analyses. Such digital approaches require a signiﬁcant
oversampling to ensure that both alleles of a diploid sample are
assessed in order to avoid technical false negatives. At the same time,
the digital nature and required oversampling of these new approaches
may allow application of an unprecedented statistical rigor to the
evaluation of sequencing data.
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